Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease

Table 2 Efficacy in the reference (racemic pantoprazole 40 mg, n = 182) and test (S-pantoprazole 20 mg, n = 187) groups

Symptoms		d 0		d 14		d 28		P3
		Ref	Test	Ref	Test	Ref	Test
Heart burn	Mean ± SD	1.8 ± 0.8	1.9 ± 0.8	1.2 ± 0.8	1.2 ± 0.9	0.6 ± 0.9	0.6 ± 0.8	< 0.0001
	Median (Percentile 25th, 75th)	2 (1.2)	2 (1.3)	1 (1.2)2	1 (0.5.2)1	0 (0.1)2	0 (0.1)1
Regurgitation	Mean ± SD	1.6 ± 0.9	1.7 ± 0.9	1.1 ± 0.8	1 ± 0.8	0.5 ± 0.8	0.4 ± 0.6	< 0.0001
	Median (Percentile 25th, 75th)	2 (1.2)	2 (1.2)	1 (0.2)2	1 (0.2)1	0 (0.1)2	0 (0.1)1
Bloating	Mean ± SD	1.4 ± 0.9	1.4 ± 1	0.9 ± 0.9	0.8 ± 0.8	0.5 ± 0.8	0.3 ± 0.6	< 0.0001
	Median (Percentile 25th, 75th)	1 (1.2)	2 (1.2)	1 (0.2)2	1 (1.2)1	0 (0.1)2	1 (1.1)1
Nausea	Mean ± SD	1.4 ± 1	1.3 ± 1	0.8 ± 0.9	0.7 ± 0.8	0.4 ± 0.8	0.4 ± 0.7	< 0.0001
	Median (Percentile 25th, 75th)	2 (0.2)	1 (0.2)	1 (0.2)2	0 (0.1)1	0 (0.0.25)2	0 (0.1)1
Dysphagia	Mean ± SD	0.3 ± 0.6	0.5 ± 0.8	0.2 ± 0.6	0.2 ± 0.5	0.1 ± 0.4	0.1 ± 0.4	< 0.001
	Median (Percentile 25th, 75th)	0 (0.0)	0 (0.1)	0 (0.0)	0 (0.0)1	0 (0.0)	0 (0.0)1

^1,2 Dunn’s multiple comparisons test; ³P value for ANOVA (Friedman’s test).